Edgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Edgestream Partners L.P. boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 21.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,249 shares of the biopharmaceutical company's stock after acquiring an additional 11,511 shares during the period. Edgestream Partners L.P.'s holdings in TG Therapeutics were worth $2,573,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TGTX. Proficio Capital Partners LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $306,000. HighTower Advisors LLC boosted its position in shares of TG Therapeutics by 19.0% during the 4th quarter. HighTower Advisors LLC now owns 14,912 shares of the biopharmaceutical company's stock worth $449,000 after purchasing an additional 2,386 shares during the period. Swiss National Bank lifted its holdings in TG Therapeutics by 0.9% during the 4th quarter. Swiss National Bank now owns 289,300 shares of the biopharmaceutical company's stock worth $8,708,000 after buying an additional 2,700 shares in the last quarter. Natixis Advisors LLC acquired a new stake in TG Therapeutics during the 4th quarter worth approximately $857,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at $216,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insiders Place Their Bets

In other news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.64% of the company's stock.

TG Therapeutics Stock Up 0.9%

Shares of NASDAQ:TGTX opened at $39.19 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. TG Therapeutics, Inc. has a 1-year low of $16.65 and a 1-year high of $46.48. The company's fifty day moving average is $36.33 and its two-hundred day moving average is $35.46. The stock has a market capitalization of $6.22 billion, a price-to-earnings ratio of 163.29 and a beta of 1.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same quarter last year, the business posted ($0.07) EPS. The business's revenue for the quarter was up 90.4% on a year-over-year basis. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.